Hepatitis C virus (HCV) is a positive-strand RNA virus of the Flaviviridae family (11) . HCV infection, affecting 3% of the world population, leads to chronic hepatitis in up to 85% of the cases, in 10 to 20% of the cases it develops into cirrhosis that requires constant treatment and provokes permanent infirmity, while 1 to 5% of chronically infected patients are diagnosed with hepatocellular carcinoma (9) . No efficient treatment exists; even the new dual therapy with pegylated interferon alpha 2a or 2b and ribavirin is effective only in up to 60% of the cases, depending on the genotype of the virus and the duration of the treatment (21) . To date, no vaccine against HCV has been developed in spite of numerous attempts and advanced trials, principally because of the high variability of the RNA genome and association of HCV particles with host lipoproteins and immunoglobulins (1, 15) . Thus, nonstructural proteins involved in viral replication are being examined as targets of antiviral therapy. One of them is NS3 (serine protease/RNA helicase), whose helicase activity is indispensable for replication of the viral RNA (25) . The helicase part of NS3 folds into three domains of comparable size (domains 1, 2, and 3) that form a triangular molecule. Five structures of the NS3 helicase have been resolved by X-ray crystallography. The latest resolved structure shows two helicases bound to a single DNA molecule and reveals an apparent interface between two protein molecules (33) . The existence of oligomeric structures of the NS3 helicase is supported by cross-linking experiments in solution (27) . A recently reported biochemical model suggests that the monomeric NS3 helicase is functional but that multiple NS3 helicase molecules are required for optimal processivity (13, 28, 44, 45) .
The main difference between all NS3 helicase structures available concerns the position of domain 2 in relation to domains 1 and 3. Domain 2 is connected to domains 1 and 3 via flexible linkers, which allow it to freely rotate relative to domains 1 and 3. In some structures, domain 2 is rotated away from domain 1 in an "open" conformation, while in other structures domain 2 is closer to domain 1 in a "closed" conformation.
All helicases crystallized to date contain domains that resemble domains 1 and 2, but none of them resembles domain 3 (16, 24) . Several experiments, e.g., the deletion of 97 amino acids from C terminus of NS3 (22) or studies on the mutation of the tryptophan residue in position 501 of NS3 (W501) (29, 42) , revealed that domain 3 is indispensable for nucleic acid (NA) binding and unwinding. The NA is bound in a negatively charged pocket between domains 1, 2, and 3. This site is not conserved in cellular enzymes and therefore might represent a promising target for the engineering of specific helicase inhibitors that are nontoxic for cell proteins.
Peptide inhibitors are quite attractive candidates for antiviral agents. It is relatively easy to design a peptide that fits a studied protein, regardless of the size and chemical properties of the target site. Moreover, in many cases it has been found that isolated peptides, whose sequences correspond to a frag-ment of a protein, have a strong tendency to adopt the same conformation as they have in the protein (14) . Selected inhibitors may lead to the development of efficient peptidomimetics to inhibit virus attachment, entry, or replication. Examples of peptide-derived inhibitors, for which the inhibitory activity was confirmed, include an interface peptide acting as a dimerization inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease (17) and enfuvirtide -HIV-1 entry inhibitor, a peptide derived from the viral envelope protein gp41 (43) . As a result of the growing knowledge concerning the structure and functions of HCV proteins and the availability of the HCV replicon system (2, 32), a subset of antiviral agents comprising direct peptide-derived inhibitors of HCV enzymes such as protease and polymerase has been developed in recent years. The most advanced peptidomimetic inhibitors are directed against the HCV NS3/4A serine protease, e.g., BILN-2061, VX-950, and SCH503034 (26, 29, 34, 46) .
A set of peptides whose sequences correspond to the arginine-rich motif VI of domain 2 of the HCV helicase (genotype 1b) have undergone detailed studies by P. Borowski et al. (6, 7) . The first experiments performed with a radioactive helicase assay revealed the inhibitory activity of these peptides (of various lengths and composition) and pointed at a peptide composed of 14 amino acids (p14, RRGRTGRGRRGIYR) as the best helicase inhibitor (P. Borowski, Polish patent application PL378824).
Here we present further studies using an overexpressed peptide and the fluorometric helicase activity assay that confirm the potent inhibitory activity of p14. The mechanism of action of the peptide was studied by using various biophysical methods. We demonstrate that p14 can inhibit replication of subgenomic HCV replicons in the Huh-7 cell culture system.
MATERIALS AND METHODS
Peptide cloning, expression, and purification. High-pressure liquid chromatography (HPLC)-purified oligonucleotides carrying the p14 peptide sequence (in boldface) with HindIII (in boldface italics) and BamHI (in italics) cohesive ends added at the 5Ј or 3Ј ends were purchased from Sigma (sense, 5Ј-AGCTT TGGATGCGCCGTGGCCGCACCGGTCGTGGTCGCCGTGGCATTTATCTG AG-3Ј; antisense, 3Ј-AACCTACGCGGCACCGGCGTGGCCAGCACCAGCGGC ACCGTAAATAGCGACTCCTAG-5Ј). An additional methionine codon (ATG) was added downstream of the 5Ј HindIII restriction site to create a cyanogen bromide (CNBr) digestion site. The insert obtained by annealing both oligonucleotides was cloned into the Hind III/BamHI sites of the pMM1436 plasmid, a derivative of pAED4 (5), fused to the sequence of a hydrophobic leader peptide (tryptophan operon with the internal deletion ⌬trpLE1413 [36] ), targeting the construct to inclusion bodies. The ligation product was introduced into the Escherichia coli DH5␣ strain by electroporation and selected on the basis of restriction digestion of isolated plasmids. The proper sequence of the construct was confirmed by sequencing. Protein overexpression was carried out in the E. coli HMS174(DE3) strain in LB medium supplemented with ampicillin (100 g/ml). An overnight culture diluted 100-fold was induced with 0.4 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) at an optical density at 600 nm of 0.8 and harvested after 3 h. The bacteria were lysed by sonication in 50 mM Tris-HCl (pH 8.8), 15% glycerol, 100 mM MgCl 2 , 10 mM MnC1 2 , and 10 g of DNase I/ml and then centrifuged. The pellet was resuspended in 50 mM Tris-HCl (pH 8.8), 1% Nonidet P-40 (NP-40), 1% deoxycholic acid, 1 mM EDTA, and 200 mM NaC1 and then sonicated and centrifuged. The pellet was dissolved in 6 M guanidine hydrochloride and 50 mM Tris-HCl (pH 8.8), sonicated, and diluted 10-fold with water. The precipitate was centrifuged, suspended in 70% formic acid, and incubated with CNBr for 2.5 h. The mixture was diluted 10-fold with water and freeze-dried. The peptide was extracted from the lyophilysate with water and purified on a semipreparative C 18 column (ZORBAX) in a 0 to 90% water-acetonitrile gradient in the presence of 0.1% trifluoroacetic acid. The concentration of the peptide was determined at 280 nm using the molar extinc- Expression and purification of recombinant proteins. The expression and purification of the full-length HCV helicase and its domain 2 were performed as previously described (4) . Domain 1 of the HCV helicase was cloned into the bifunctional YpET-30a vector, a recombinant of pET-30a (Clontech) and pFL38, kindly provided by M. Zagulski (Institute of Biochemistry and Biophysics [IBB]), by using homologous recombination in the Saccharomyces cerevisiae BY strain. This method relies on plasmid gap-repair by PCR-generated cassettes (50) . Oligonucleotide primers were obtained from the Laboratory of DNA Sequencing and Oligonucleotide Synthesis, IBB. The HCV-1 cDNA template (accession no. AAA45676) (23) was used to PCR amplify domain 1 with a sense primer (GTTTAACTTTAAGAAGGAGATATACATATGGTGGACTTTAT CCCTGT GGAG) and an antisense primer (CGGATCTCAGTGGTGGTGGTGGTGGT GAGGGGTGGCGGTGGCGAGC) that covered the His 6 tag coding sequence from the vector (nucleotides corresponding to the sequence of domain 1 are indicated in boldface). Total DNA was isolated from yeast; recombinant plasmids were identified by PCR and amplified in E. coli DH5␣. The correct sequence of the construct was confirmed by restriction digestion and sequencing. Protein overexpression was carried out in the E. coli BL21(DE3)/LysE strain in LB medium supplemented with kanamycin (50 g/ml). Cells were grown at 37°C until the cultures reached an optical density at 600 nm of ϳ1.0; they were induced with 1 mM IPTG and harvested after 4 h at 37°C. The recombinant protein was purified according to the protocol established for proteins purified from insect cell cultures (4) . The concentration of the HCV helicase domain 1 was determined at 280 nm using the molar extinction coefficient of 7,680 M Ϫ1 cm Ϫ1 , which was calculated on the basis of protein composition by the ProtParam program. Extracts and eluates were analyzed by 15% SDS-PAGE, and proteins were visualized by Coomassie blue staining.
Peptide CD analysis. Far UV-circular dichroism (CD) spectra were measured in a cell with a 10-mm path length at 200 to 270 nm with an AVIV 202 spectropolarimeter. The sample of 10 M peptide was prepared in 50 mM sodium phosphate buffer (pH 7.6) and 0.3 M NaCl. The experimental parameters were as follows: temperature, 25°C; bandwidth, 1 nm; wavelength step, 1 nm; and averaging time, 3 s.
Helicase assay. The fluorometric assay was performed as described by Boguszewska-Chachulska et al. (3) , with some modifications. Helicase assays (in 60 l) were performed in 30 mM Tris-HCl (pH 7.5), 6 mM MnCl 2 , 0.075% Triton X-100, and 0.05% sodium azide, with 10 nM double-stranded DNA (dsDNA) substrate, 1.5 mM ATP, and 125 nM capture strand. The enzyme (10 nM) was preincubated with the peptide without ATP for 15 min at the room temperature. The unwinding reaction was started by the addition of ATP and was carried out at 37°C for 60 min in a Synergy HTi fluorescence reader (Biotek).
ATPase assay. The ATPase assay was performed as described previously (3, 4 ). The peptide was tested up to a concentration of 100 M. The reactions were carried out in 25 l of reaction buffer with 100 nM helicase for 60 min at 30°C.
Cross-linking protocol. Cross-linking reactions were carried out in 15 l in a solution composed of 50 mM HEPES (pH 8.0), 150 mM NaCl, and 6 mM freshly prepared sulfo-EGS (Pierce). The protein concentrations were 20 and 80 M for the NS3 helicase and the peptide, respectively. Some samples were supplemented with 1 mM ATP and 6 mM Mn 2ϩ or with dsDNA with a 5Ј five-base single-stranded DNA and a 3Ј five-base single-stranded DNA tail. The DNA concentration varied between 0.2 and 2.6 M, depending on the sample. After 30 min of incubation at room temperature, the reactions were quenched by addition of 7 l of 3ϫ gel loading buffer (0.2 M Tris-HCl [pH 6.8], 8% SDS, 2.88 M ␤-mercaptoethanol, 40% glycerol, 0.4% xylene cyanol, and 0.4% bromophenol blue), the samples were boiled for 3 min, and then separated by 15% SDS-PAGE. Proteins were visualized by Coomassie blue staining, whereas DNA was visualized by UV light at 254 nm in the gel placed on a silica gel chromatography plate (Merck Art. 5735).
NMR studies. Nuclear magnetic resonance (NMR) experiments were performed on Varian Unity ϩ 500, Varian Inova 400, Varian Inova 750, and Bruker AvanceII 750 NMR spectrometers. The NMR spectrometers were equipped at least in three channels, a gradient unit in the z direction, and an inverse 1 H/ 13 C/ 15 N probehead. The cryo probehead was used to record the NMR spectra on a Bruker AvanceII NMR spectrometer. The temperature was stabilized at 277 K in all measurements unless otherwise indicated. The 1 H, 13 C, and 15 N chemical shifts reported were referenced using external DSS (2,2-dimethyl-2-silapentane-5-sulfonate sodium salt), where 13 C and 15 N signals were referenced indirectly using 0.251449530 and 0.101329118 ratios for 13 C and 15 N nuclei, respectively 394 GOZDEK ET AL. ANTIMICROB. AGENTS CHEMOTHER. (49) . All NMR datasets were processed by using the NMRPipe software (12) and analyzed with the aid of the SPARKY program (18) . p14 peptide assignments. The 15 N-labeled p14 peptide was obtained by growing bacteria in M9 medium supplemented with a mixture of vitamins (5 g of thiamine, 1 g of biotin, 1 g of choline chloride, 1 g of folic acid, 1 g of nicinamide, 1 g of calcium pantothenate, 1 g of pyridoxal, and 0.1 g of riboflavine/ml), 1 mM MgSO 4 , 0.1 mM CaCl 2 , 0.001 mM FeCl 3 , and 0.08% 15 NH 4 Cl. To prepare an NMR sample, 15 N-labeled peptide was dissolved in 90%/10% H 2 O/D 2 O, 50 mM phosphate buffer, and 200 mM KCl to a final 0.8 mM concentration. The pH was stabilized at 6.5 or 7.5 (uncorrected values). The two-dimensional (2D) NMR spectra were recorded on a Varian Unity ϩ 500 NMR spectrometer at 298 K. The homonuclear 2D total correlation spectroscopy (TOCSY) and 2D rotating-frame Overhauser enhancement spectroscopy (ROESY) experiments were recorded with mixing times 80 and 300 ms, respectively. The spectral widths of 6,000 Hz in both dimensions were used to record 1024 ϫ 256 complex data points in 1 and 2 frequencies, respectively. The 2D 1 H-15 N heteronuclear single quantum correlation (HSQC) spectrum was recorded with 6,000 ϫ 1,600 Hz spectral widths and 1,024 ϫ 128 complex data points in the 1 H and 15 N directions, respectively. Studies on p14 binding to the HCV helicase and its domains. The interaction of the HCV helicase, domains 1 and 2, with the peptide was evaluated by using the T 2 relaxation filtered NMR technique (20) . The experiments were performed on either a Varian Unityϩ 500 or a Varian Inova 400 NMR spectrometer. A typical NMR sample was prepared by diluting the proteins to 0.1 mM in 90%/ 10% H 2 O/D 2 O, 50 mM phosphate buffer and 200 mM KCl. The pH was stabilized at 7.5 (uncorrected value). Peptide-protein complex formation was traced after the addition of 0.1 to 0.3 mM peptide from a stock solution. The process of binding of the peptide to either the full-length HCV helicase or domains 1 and 2 was traced by comparative analysis of 1 H 1D NMR spectra recorded with or without a T 2 relaxation filter (20) . We usually used 128 scans, a 1.4-s recycle delay, and T 2 relaxation filters as long as 400 ms in these experiments.
Sequence-specific assignment of HCV helicase domain 1. 
where ⌬␦ N and ⌬␦ H are the chemical shift differences of nitrogen and hydrogen, respectively. A weighting factor of 5 was used because the spectrum width of 15 N is about fivefold larger than that of 1 H. Geometry optimization. Interacting residues were identified and mapped on the domain 1 structure derived from the Protein Data Bank (PDB ID 2F55) (33) , while initial coordinates of the peptide were obtained on the basis of the domain 2 fragment R461 to R474 from the same helicase structure (the amino acid positions are those of the full-length NS3 protein), with the exchange of one amino acid (S470 in the NS3 sequence to R10 in the peptide sequence). The peptide in its extended conformation was docked to domain 1 on the side found on the basis of limited data from titration experiments, with the aid of the X-PLOR program (10) . A total of 995 structures were generated by using the simulated annealing protocol (38, 39) . During the search of possible geometries the backbone structure of the protein in the complex was fixed, but the side chains were allowed to move. The final structures of the complexes were obtained by the Powell algorithm of energy minimization implemented in the X-PLOR package (10) . All simulations were based on standard X-PLOR "parallhdg" and "topallhdg" topology and parameter files. Upon initial rounds of simulations, the only distance restraints were applied for Y13 in p14 that appeared strongly bound based on the NMR titration data, and F238 and Y241 were selected as its putative partners in domain 1. Based on the population analysis of various intermolecular salt bridges, the most abundant bridges were introduced as the distance restraints used in the next rounds of simulated annealing protocol. Finally, a total of 995 rounds of simulated annealing using five distance restraints were performed to obtain the final model of the peptide complexed with domain 1. In 199 of 995 simulations an additional constraint on the distance between I12 and L236 was applied, but this raised the energy significantly. The best 20 structures, chosen based on the criterion of the lowest energy of the complex, were selected as representations of the complex structure (the structure of the lowest energy is presented). We adopted these results to predict a model of binding of the peptide to the full-length helicase.
Cells and viruses. The human hepatoma cell line Huh-7 and the plasmid pFK-luc-ubi-neo/NS3-3Ј/Con1/5.1 carrying the subgenomic HCV genotype 1 (con1) replicon with the luc-ubi-neo (reporter/selective) fusion gene (47) were kindly provided by R. Bartenschlager (Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany). Stable Huh-7 clones carrying persistently replicating subgenomic HCV replicons were obtained using the protocol described by Lohmann et al. (31) with minor modifications. Huh-7 cells were grown in Dulbecco modified essential medium (DMEM; Invitrogen) with a high glucose concentration (4.5 g/liter), supplemented with 2 mM L-glutamine, 1ϫ nonessential amino acids, 100 U of penicillin/ml, 100 g of streptomycin/ml, and 10% fetal bovine serum (Sigma); for cells carrying the luc-ubi-neo replicon, 250 g G418 (Geneticin; Invitrogen)/ml was added to the medium. Cells were grown at 37°C in 5% CO 2 .
Anti-HCV replicon studies. The conditions of the assay applied to test the antiviral activity of the peptide were based on the protocol developed by Paeshuyse et al. (40) . Briefly, a logarithmic culture of replicon-carrying cells was grown, the cells were then seeded at the density of 5 ϫ 10 3 cells per well in a 96-well tissue culture-treated white optical bottom plate (Nunc) in complete DMEM supplemented with 250 g of G418/ml. After 24 h at 37°C, the medium was removed, and serial dilutions of the inhibitor (1, 4, 20, 40 , 60, 80, and 160 M) were added in 100 l of fresh DMEM without G418. For comparison, serial dilutions of the control peptide YEVHHQKLVFFAEDV, expressed and purified as p14 (kindly provided by E. Gospodarska [IBB]), and ribavirin (ICN Biochemicals) were used at concentrations of 1, 4, 10, 20, 40, 80, and 160 M and 20, 50, 100, 200, 250, 500, and 1,000 M, respectively. After 4 days at 37°C, the medium was removed, and 40 l of 1:1 Glo lysis buffer and Bright-Glo luciferase assay system solution (Promega) were added to each well. After 2 min of incubation, the luminescence was measured in a Synergy HTi (Biotek). The experiment was carried out five times with three replicates for each compound concentration. The 50% effective concentration (EC 50 ) was defined as the peptide concentration that reduced luminescence by 50%.
Cytotoxicity assay. As in the replicon assay, the Huh-7 cells carrying the replicon were seeded at a density of 5 ϫ 10 3 cells per well in 96-well tissue culture-treated plates (Sarstedt) in complete DMEM supplemented with 250 g of G418/ml. After 24 h at 37°C, the medium was removed, and serial dilutions of the inhibitor or controls were added in 100 l of fresh DMEM without G418. After 3 days at 37°C, the medium was removed, and 100 l of DMEM with 0.5 mg of thiazolyl blue tetrazolium bromide (MTT; Sigma)/ml was added. The plates were incubated for 3 to 4 h at 37°C, the medium with MTT was removed, and 100 l of 0.04 N HCl in absolute isopropanol was added to solubilize the precipitated converted dye. The absorbance of the dye was measured at 570 nm and the absorbance of the background at 650 nm, by using a Synergy HTi (Biotek). The experiment was carried out five times with three replicates for each compound concentration. After background subtraction, 50% cytotoxic concentration (CC 50 ) was calculated as the concentration of the compound that inhibited cell growth by 50%.
RESULTS
Peptide expression, purification, and structural analysis. The peptide (p14) of 14 amino acids (RRGRTGRGRRGI YR), expressed in bacterial cells as a fusion with a hydrophobic leader peptide, was separated from the leader by CNBr cleavage and purified by HPLC (Fig. 1 ) with a yield of about 4 mg per liter and a high degree of purity (ca. 99%) that was additionally confirmed by mass spectroscopy. The peptide was fur- To test the inhibitory activity of p14, the fluorometric helicase activity assay was applied, as described by Boguszewska-Chachulska et al. (3) . The compound was tested at 0.05 to 1.6 M as shown in Fig. 2 . The inhibitory activity of the peptide varied considerably from one experiment to another, probably due to peptide instability. The IC 50 value was 725 Ϯ 109 nM, indicating that the peptide is a very efficient NS3 helicase inhibitor.
Additional experiments were designed to determine the mechanism of peptide action on helicase activity (Fig. 3) . The first experiment was performed with various enzyme concentrations (10, 20, and 40 nM; Fig. 3A) , and the second one with various substrate concentrations (10, 20, 40, and 80 nM; Fig.  3B ); in both experiments the same constant concentration of peptide (800 nM) was used, close to its IC 50 value. The results are presented as the percent activity of the helicase tested in the same conditions without the inhibitor. The results indicate that the level of inhibition strongly depends on the enzyme concentration because increasing concentrations of helicase reduce the inhibitory effect of the peptide, abolishing it completely at 40 nM helicase. It seems, however, that a possible interaction (or competition) with dsDNA is not of such importance because an eightfold increase in substrate concentration (to 80 nM) is unable to suppress the inhibition. The results obtained suggest that direct binding of the peptide to the enzyme occurs.
ATPase assay. Various concentrations of the peptide (1, 5, 10, 50, and 100 M) were tested in three independent experiments consisting of two replicates each. The results are presented as the percent activity of the helicase tested without the inhibitor in the same conditions (Fig. 3C) . No inhibitory effect was observed in the range of peptide concentrations tested. Thus, it seems that the mechanism of action of the peptide is not correlated with inhibition of the ATPase activity of the HCV helicase.
Cross-linking studies. The oligomerization of NS3, as well as interaction between the peptide inhibitor and the helicase, was investigated by protein-protein cross-linking using sulfo-EGS (NHS ester), which is a homobifunctional water-soluble cross-linking agent with a spacer length of 16.1 Å. This reagent enters the reaction with the amino group at the N terminus and the side chain amino groups of the lysine residues in the protein (there are 16 lysine residues in the NS3 helicase) and forms stable amide bonds, along with the release of the Nhydroxysulfosuccinimide group. Cross-linking studies with the NS3 helicase (20 M) and the cross-linker sulfo-EGS (6 mM) produced higher-molecular-weight bands that could correspond to helicase dimers (Fig. 4) . The presence of DNA in the samples significantly increased the amount of dimer form (lanes 4, 5, and 6). In lane 15 with the peptide and DNA without helicase, the migration of 50% of the peptide was retarded, indicating that cross-linking between the peptide and DNA occurred. Other factors such as the presence of ATP or Mg 2ϩ had no detectable effect on the efficiency of formation or distribution of the cross-linking products (lines 9 and 10). Our results demonstrate that DNA contributes to dimer formation and that the presence of ATP or Mn 2ϩ does not influence dimerization. The peptide (80 M) prevented the formation of the helicase dimer. Moreover, the presence of both the protein and the peptide prevented interaction between the peptide and the DNA. This suggests direct interaction between the peptide and the helicase. NMR studies. The 1 H and 15 N resonance assignment for the p14 peptide was based on a combination of 2D ROESY, 2D TOCSY, and 15 N-1 H HSQC experiments using a standard approach. Despite the strong overlap of arginine 1 H resonances, 12 of the 13 signals expected in 15 N-1 H HSQC spectrum were detected and unequivocally assigned. The remaining resonance of R2 was detected only in a low-pH peptide solution. Direct comparison of the 1 H NMR spectra of the peptide recorded in the presence of the helicase and its domain 2 to that of the free peptide revealed changes in the peptide spectrum induced by addition of the protein. A significant movement was observed for the well-separated I12 aliphatic resonances, which fortunately did not overlap with the proteinoriginating signals. Addition of the full-length helicase to the peptide solution caused disappearance of the two I12 resonance signals (Fig. 5, marked by arrows) , whereas almost no effect was observed when domain 2 was added. This clearly indicates that domain 2 is not a target for the interaction with p14. The 1D T 2 relaxation filtering experiments (20) helicase demonstrated efficient binding of the peptide to domain 1 (data not shown).
The comparison of a series of 15 N-1 H HSQC spectra recorded for p14 displayed the existence of small, but noticeable changes induced upon addition of domain 1 of the HCV helicase (Fig. 6A ). This effect was attributed mostly to the 12 IYR 14 fragment, pointing to the C-terminal part of the peptide as crucial for the interaction with the NS3 helicase and its domains.
The interaction of p14 with domain 1 of the HCV helicase was also monitored on the 2D 1 H-15 N HSQC spectrum of the 15 N enriched protein titrated by the p14 solution. The spectra of the protein alone and with the unlabeled peptide, acquired to detect putative interacting residues, are presented in Fig.  6B . The assignment was based on a simple "pattern matching" with the previously recorded 1 H-15 N HSQC spectrum of domain 1. About 82% of nonproline amino acids were assigned to the signals on the 1 H-15 N HSQC spectrum of domain 1. A full assignment was not achieved because the spectrum lacked 23 signals and, moreover, two amino acids in our domain 1 construct were different than in the construct described by Liu and Wyss (30) , and one methionine was added at the N terminus. According to Liu and Wyss (30) , 12 of the missing peaks are presumed to originate from the N-terminal region comprising amino acids T185 to S189 and from the Walker A motif of the conserved sequence, corresponding to amino acids T205 to S211. These resonances probably appeared in the spectrum of domain 1 with the peptide in the region limited by chemical shifts of nitrogen (109 to 111 ppm) and hydrogen (8.3 to 8.7 ppm) (Fig. 6B) . The regions mentioned above are in an extended conformation; 34 peaks that changed their positions are depicted in Fig. 6B . The perturbations of the total chemical shift calculated are presented in Fig. 7 . Since the full assignment of both peptide-bound and free domain 1 could not be obtained, for peaks that were assigned only in one spectrum http://aac.asm.org/ the chemical shift difference was measured as the distance to the nearest peak to determine the lower limitation of the perturbation (48) . For six residues the change in resonance location, ⌬␦, exceeded 0.1 ppm: H201, H203, A233, C292, and two others that could not be identified. Five residues displayed ⌬␦ in the range of 0.04 to 0.1 ppm: K244, D285, and three other residues that could not be unambiguously assigned. For the remaining residues, changes in ⌬␦ did not exceed 0.04 ppm.
The residues putatively interacting with p14 are clustered in four regions at the surface of domain 1, all of them located close to the domain 1 and 2 interface in the entire NS3 helicase. This clustering is reflected in their ⌬␦ distribution ( Fig.  7 ): A233 to K244 represent a part of an ␣-helix, while three adjacent parts correspond to the N-terminal ␤-sheet (V199 to H203), the C-terminal residues (L320 to A323) and the metal ion-binding loop (D290 to C292). The residues of highest interest are H201, H203, A233, D285, K244, and C292, which surround an acidic area with the exception of D285. Taking into account that the size of the peptide limits the area of interaction, we conclude that some chemical shift differences arise only from conformational changes in protein structure only upon peptide binding and are not due to peptide proximity.
For peptide docking to domain 1 the following restraints were chosen. The only tyrosine in the peptide was fixed inside a cavity between F238 and Y241. Four salt bridges between the protein's acids and the peptide's arginines were fixed as follows: R14 to D290, R9 to E291, R7 to D296, and R1 to D308 (Fig. 8A ). This selection is rather arbitrary but supported by two facts. First, the peptide spreads close to the residues identified as binding sites and, second, according to the map of potential energy, the proposed restraints place the peptide in the negatively charged pocket between domains 1, 2, and 3 that constitutes a good target for the positively charged peptide.
NS3 peptide is an inhibitor of subgenomic HCV replication in Huh-7 cells. The subgenomic HCV replicon I389 luc-ubineo/NS3-3Ј/Con1/5.1, used here, carries the HCV 5Ј untranslated region with the internal ribosome entry site directing the expression of a luc-ubi-neo fusion gene, an internal ribosome entry site from encephalomyocarditis virus that directs translation of the HCV NS3 to NS5B region, and the HCV 3Ј untranslated region. The expression of luc-ubi-neo gene enables the concurrent selection of neomycin/G418-resistant cells with replicating HCV RNA and measurement of RNA replication by using an indirect but easy and sensitive method, based on the determination of the activity of the reporter protein luciferase (47) . Replicon-bearing cells were treated for 4 days with concentrations of p14 and control peptide ranging from 1 to 160 M and of ribavirin ranging from 50 to 1,000 M. The level of HCV RNA replication remaining in the cells was determined by measuring the luminescence signal. The addition of p14 reduced the level of HCV RNA in a dosedependent manner. Concentrations of the peptide up to 60 M significantly inhibited HCV RNA replication, and simultaneously no cytotoxic effect was observed. The presence of the peptide even intensified cell growth by ca. 20% compared to control cells. A similar observation was made for IFN alfa-2b (Schering-Plough)-treated cells, as well as for other helicase inhibitors studied in the replicon system (data not shown). We assume that this is correlated with replicon loss since this effect was not observed for Huh-7 cells without the replicon. The EC 50 , CC 50 , and therapeutic index (TI; i.e., CC 50 /EC 50 ) values obtained for p14, control peptide, and ribavirin are listed in Table 1 . In comparison to other compounds in development, e.g., VX-950 with an EC 50 Moreover, the results of HCV replication inhibition have been presented solely for already-modified peptides (26, 29) , and these values should not be compared to those for an unmodified peptide.
DISCUSSION
As presented above, the p14 peptide possesses a potent anti-helicase activity with an IC 50 of 725 nM in the fluorometric helicase activity assay, indicating that it is one of the most efficient NS3 helicase inhibitors cited in the literature (3, 8, 19) , as well as when compared to other inhibitors tested in the same system, for which IC 50 values exceeded 17 M (3). Subsequent experiments with various concentrations of the enzyme and substrate enabled us to reveal more facts on the mechanism of action of the peptide. The experiment with increasing enzyme concentrations at constant inhibitor concentration suggested the possibility of direct binding of the peptide to the helicase. Simultaneously, a similar experiment with increasing substrate concentrations indicated that the level of inhibition was independent of substrate concentration. The direct interaction between the peptide and helicase was confirmed by further NMR studies. According to Dyson and Wright (14) , peptide fragments of proteins can adopt their native structures in solution. Our preliminary explanation of how p14 inhibits the helicase activity assumed that the free peptide might mimic part of domain 2 and thus interact with domain 1 (via an ATP molecule) as does the original helicase motif VI. Thus, interference by the peptide might prevent movements of domain 2 in relation to other domains of the helicase and therefore cause enzyme inhibition. However, our CD and NMR measurements showed that p14 adopted random coil structures and that this tendency was independent of the presence or absence of helicase in the solution. Thus, the mechanism of inhibition could be different. The comparison of the 1 H NMR spectra of the p14 peptide recorded in the presence of the entire helicase and its domain 2 to that of the free peptide indicates that the peptide binds to the full-length enzyme while domain 2 is not a target of interaction. Consequently, during subsequent NMR studies we focused only on the interaction between the peptide and domain 1. The results of relaxation filtering experiments performed for p14 alone and for p14 in the presence of domain 1 indicate that p14 efficiently binds to domain 1 of the HCV helicase. A comparison of a series of 15 N-1 H HSQC spectra recorded for the peptide alone and upon addition of domain 1, as well as a series of spectra recorded for the 15 N-labeled domain 1 alone and with the peptide, allowed us to identify the principal amino acid residues on both molecules engaged in this interaction. The peptide residues crucial for helicase binding are Y13 that anchors the C-terminal part of p14 in the hydrophobic pocket on domain 1 and the adjacent amino acids I12 and R14. These NMR data drove us to create a model of the peptide-domain 1 interaction (Fig. 8A ) and, on this basis, to create a model of the peptide-helicase binding (Fig. 8B) . According to this model, the p14 peptide in its extended conformation is twisted around domain 1, partially filling the clefts between domain 1 and domain 2, as well as between domain 1 and domain 3. In this position the peptide should not affect the ATPase activity of the helicase. This result is supported by the ATPase assay, clearly indicating that the peptide does not inhibit the NS3 ATPase activity. Moreover, some of peptide arginines may coordinate ATP binding and hydrolysis, instead of the arginine from motif VI of domain 2. Several significant changes in chemical shift were observed in the part of the domain 1 facing domain 3 (Fig. 8A) . The part of the peptide interacting with the interface between these two domains certainly prevents NA from binding the helicase. At least two amino acids (T269 and W501, Fig. 8B ) crucial for NA binding are blocked while the peptide is bound to the helicase. Our results from cross-linking experiments strongly support these assumptions. According to Levin and Patel (27) the helicase alone is capable of forming oligomers, but in the presence of DNA most of the helicase molecules form dimers. Mackintosh et al. (33) crystallized the helicase dimer bound to a single oligonucleotide (PDB ID 2F55). In the dimer structure, the oligonucleotide is bound to each helicase particle within the cleft formed at the interface of domains 1 and 2 with domain 3. Our results confirmed the observation concerning the contribution of DNA to dimer formation and the fact that the presence of ATP or Mn 2ϩ did not influence dimerization. The presence of the peptide disabled formation of the helicase dimer. Moreover, the presence of both the protein and the peptide prevented interaction between the peptide and the DNA (Fig. 4) . This suggests direct interaction between the peptide and the helicase and clearly proves that the interaction occurs through the same interface as DNA binding. In our opinion the mechanism of peptide inhibition mainly relies on blocking the NA binding site. One of the plausible hypotheses assumes that an interaction between these three molecules may occur when the helicase encounters the NA-bound peptide during its translocation along the NA (similarly to streptavidin displacement from 5Ј-biotinylated oligonucleotides) (37) .
Our results from the HCV replicon system indicate that the p14 peptide reduces HCV RNA replication in a dose-dependent manner, although the window between inhibition of RNA replication and cytotoxicity is narrow (TI ϭ 1.8). The impact of the peptide on replicon cells varied among the five experiments performed, in some experiments even giving EC 50 values as low as 40 M. The precise EC 50 is difficult to assess since the peptide may aggregate or undergo disintegration. Thus, the actual TI can be higher than calculated on the basis of the experiments performed. Peptide cytotoxicity may be due to the kinase inhibitory activity of the peptide, as well as to interaction of the peptide with cellular NA, but possible peptide aggregation might also be involved in these effects. Argininerich peptides can enter cells with high efficiency, but mainly by endocytosis, followed by partial degradation in endosomes (35) . Thus, the difference between EC 50 and IC 50 may be a result of p14 degradation by cellular proteases and aggregation. Still p14 has a better TI than ribavirin in our HCV replicon system and, as a positively charged peptide, it can efficiently penetrate cells. Therefore, we consider it to be a good starting point for the design of anti-helicase peptidomimetic agents with improved stability in the cell and thus enhanced anti-HCV activity. Modified p14 could be used as a component of a multidrug anti-HCV therapy that would target various viral proteins, since it is one of the most efficient anti-helicase agents published and the only one for which the antiviral activity was demonstrated to date.
